For example, NSCLC patients with epidermal growth factor receptor (EGFR) mutations have shown a dramatic response to EGFR inhibitors such as gefitinib and erlotinib (Mok et al, 2009; Maemondo et al, 2010). This evidence concerns the gene EGFR and non-small cell lung carcinoma.